Nazzi Gianfranco 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 19, 2020
Insider Transaction Report
Form 4
Nazzi Gianfranco
EVP, Growth Markets Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
2020-03-17+874→ 20,189.357 total - Sale
Ordinary Shares
2020-03-17$7.17/sh−345$2,474→ 19,844.357 total - Exercise/Conversion
Restricted Share Units
2020-03-17−874→ 0 total→ Ordinary Shares (874 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.2000, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 17, 2016, with 872 vesting on each of March 17, 2018 and March 17, 2019 and 874 vesting on March 17, 2020.